Why Skills Alliance Is Betting Big on AI

Q&A With Mike Chapman, CTO, Skills Alliance

Q: Why has Skills Alliance made a significant investment in technology and AI right now?

The timing is deliberate. We are at an inflection point in the history of recruitment. ChatGPT reached 100 million users in just two months – a milestone that took the telephone 75 years to achieve. The pace of AI advancement is not linear; it is exponential, and the life sciences and STEM sectors we serve are feeling that acutely.

If we are going to help our clients attract the best talent in biotech, pharma, clinical research and engineering, we need to operate with the intelligence and speed that those industries demand. Investing in technology and AI is the clearest signal we can send, that it is no longer a support function at Skills Alliance – it is a core commercial strategy to deliver competitive advantage to our customers.

Q: What does AI actually change for a specialist recruiter like Skills Alliance?

Quite simply, it changes everything about how we find, assess and engage talent. The global pool of specialists – say, mRNA platform biologists or QP-qualified regulatory affairs professionals – can be fewer than 500 people worldwide. Knowing who those people are, where they are in their career cycle, and what would motivate them to move is enormously valuable intelligence.

AI-powered sourcing tools can map that entire talent universe in minutes, including passive candidates who have not updated a single profile. Predictive mobility models can identify who is likely to consider a move before they even know it themselves. That means our consultants can call first, and our clients get access to the right people faster with hyper personnalised automated messaging through multiple channels.

Q: How does investing in technology benefit Skills Alliance’s clients in life sciences and STEM?

Speed and precision are the two outcomes clients care about most. In highly regulated sectors such as pharmaceuticals and medical devices, a delayed hire can hold up a clinical trial or a product launch – the commercial consequences are real. Our technology investment means we can respond to a brief in minutes rather than days, presenting verified candidates with context: warm relationships, prior placements, compensation benchmarks, and career signals that go far beyond a CV.

We are also building proprietary talent intelligence on the market rather than relying entirely on third-party platforms. The companies that own the richest data on specialist talent will win those roles consistently. That is what we are building a unique data set and insight that cannot be matched through publicly available source that our competition use.

Q: What does this technology investment mean for consultants working at Skills Alliance – how does it change their day-to-day experience?

This is something I feel strongly about, because technology investment only delivers if the people using it are genuinely better at their jobs as a result. For our consultants, the shift is from grinding through manual sourcing and repetitive outreach to spending the majority of their time doing the work that actually builds a career: having strategic conversations, developing trusted relationships with clients, and guiding candidates through some of the most important decisions of their professional lives. The AI handles the volume work – the sourcing, the screening, the first-pass outreach at scale. The consultant becomes a talent strategist, the human connection that no model can replicate.

Beyond the day-to-day, this shapes the kind of business consultants want to join and stay in. Skills Alliance is investing in becoming a high-tech, high-impact environment – one where people are equipped with superior tools, trained to use them well, and trusted to focus on the relationships that define this industry. For consultants who are serious about building a long-term career in life sciences or STEM recruitment, that is a genuinely compelling proposition. The best people want to work somewhere that takes their development and their tools seriously. This is how we attract them, and how we keep them.

Q: What is the risk for life sciences and STEM businesses that do not embrace AI-driven recruitment partners?

The Goldman Sachs estimate, that 300 million jobs could be automated this decade, should give every business leader pause. In recruitment terms, the manual, linear process – post a role, screen CVs, phone candidates – is already being outpaced by competitors using AI at every step. A recruitment partner still operating that way will consistently lose the best candidates to faster, smarter competitors.

For life sciences and STEM clients, where the talent market is already highly competitive and the candidate pool is genuinely small, that is an unacceptable risk. The firms that win will be those who combine human expertise with AI-powered intelligence. Skills Alliance is building exactly that combination.

Q: What is your vision for what Skills Alliance looks like as a technology-enabled recruiter in 12 months?

Our mission is clear: best data, best tools, best training, best results. In practical terms, that means our consultants open their day with an AI-generated briefing on which candidates in their market are most likely to be considering a move. It means a client can call us for a gene therapy CMC specialist and we respond in minutes with a shortlist of verified, warm candidates – not a search we are just starting. It means a meaningful proportion of our placements come from intelligence we own, rather than renting access to data through third-party platforms.

Technology should be the bridge that lets our consultants do what they do best: build lasting human connections in some of the most important industries in the world. That is the future we are building, and we are building it now.

Skills Alliance is a global leader in life sciences and STEM workforce solutions. The appointment of Mike Chapman as CTO signals the company’s continued commitment to technology-led recruitment for clients and candidates across biotech, pharma, clinical research, and engineering.